% | $
Quotes you view appear here for quick access.

ZIOPHARM Oncology, Inc. Message Board

  • stoksboks stoksboks Feb 1, 2013 3:35 PM Flag

    opinions please-- ZIOP v THLD

    Hi everyone. I'm looking to open a position in Ziop and/or THLD. Wondering if anyone had any thoughts on which is the smarter play. I realize ZIOP has a catalyst coming up soon, but THLD seems to have a promising pipeline as well. Thanks for any educated thoughts/discussion!!!

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • THLD's pipeline is limited to its one drug (TH-302) - that drug, like ZIOP's palifosfamide has the potential to be used in a broad range of cancers, so it is not limited to just pancreatic or STS, for which TH-302 is in Phase III. If ZIOP's upcoming Phase III trial results in pali are positive, it clearly will be a big winner and eliminate any funding issues - they indicated in the last presentation that the cash on hand covers them through "the second half of 2013". If the trial is not successful, then you will be looking at a share price probably below $3 and the need to raise funds before year-end. THLD does not have any funding issues, as they have a JV with Merck, who is funding 70% of the clinical development of TH-302. Bottom line - ZIOP is a higher risk and higher reward play at this stage and from what I have read about their synthetic biology platform, the long-term value of that technology is well beyond the value of palifosfamide. BTW, I consider the risk associated with the current pali trial to be rather low - i.e. there is enough clinical evidence to show that pali should drive a 3+ month increase in PFS, the trial is large enough to weed out any aberrations in the control arm, and the safety profile of pali is clean enough to avoid any safety disasters.

      • 1 Reply to tredleon
      • Thanks for the reply, Tredleon. Lots to consider for ZIOP-- especially the future of the IL-12 pipeline-- amazing potential.

        I had a question about Pali for those who understand the science more. Basically, how does Pali differentiate between attacking the tumor DNA and normal healthy DNA? Clearly, the phase II data shows that Pali is effective, but I don't quite understand the mechanism in which Pali seeks out cancerous tumors. Thanks for explaining to this investor who almost understands, lol...

5.49-0.27(-4.69%)Sep 26 4:00 PMEDT